论文部分内容阅读
目的 探讨康莱特注射乳剂与联合化疗治疗非小细胞肺癌疗效及毒副反应。方法 将82例非小细胞肺癌分为两组,康莱特乳剂(KLT)加联合化疗组38例,化疗方案为顺铂60mg静注,连用2天,长春新碱2mg,第1、8天静注,丝裂霉素6mg,第1天静注,KLT200ml,静滴连用20天,每周期间隔21至28天,均应用2个周期以上;联合化疗组PVM44例,仅用PVM联合化疗2个周期以上。结果 两组总有效率29.3%,其中,KLT组有效率42%(16/38),PVM组有效率18%(8/44),两组差异有显著性(P<0.05)。两组化疗前后一般状况改变(KPS)差异有显著性(P<0.05)。静滴康莱特注射乳剂后少数患者可有轻度恶心、发热、寒颤、皮疹,使用3至5天后大多可自然消失而适应,偶见静脉炎,改用锁骨下静脉穿刺置管滴注可以避免。结论 KLT合并联合化疗可显著提高非小细胞肺癌的疗效,康莱特注射乳剂无明显毒副反应。
Objective To investigate the curative effect and toxicity of Kanglaite Injection and combination chemotherapy in non-small cell lung cancer. Methods 82 cases of non-small cell lung cancer were divided into two groups. 38 cases were treated with KLT combined with chemotherapy, and the chemotherapy regimen was cisplatin 60 mg intravenously for 2 days, vincristine 2 mg, Note, mitomycin 6mg, the first day of intravenous injection, KLT200ml, intravenous infusion of 20 days, every interval of 21 to 28 days, are applied more than 2 cycles; combined chemotherapy group of PVM 44 cases, only PVM combined with chemotherapy 2 Cycle above. Results The total effective rate was 29.3% in both groups, of which the effective rate was 42% (16/38) in KLT group and 18% (8/44) in PVM group. There was significant difference between the two groups (P <0.05). There were significant differences in KPS between the two groups before and after chemotherapy (P <0.05). Intravenous infusion of Kanglaite injection of a small number of patients may have mild nausea, fever, shivering, rash, the use of 3 to 5 days most of the natural disappearance and adaptation, occasionally phlebitis, switch to subclavian vein catheterization infusion can be avoided . Conclusion KLT combined with chemotherapy can significantly improve the efficacy of non-small cell lung cancer, Kanglaite injection emulsion no obvious side effects.